Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Triple-Negative Breast Cancer
Clinical trial register · United States · industry-sponsored

Triple-Negative Breast Cancer Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9129 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 03 Nov 2026, 03:16 UTC
9129
Studies in scope
industry-sponsored, all four open statuses
4971
Recruiting now
open to new participants
2191
Lead sponsors
across recruiting studies
Top states
California 14 Florida 12 Georgia 11 Colorado 9 Texas 8
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Triple-Negative Breast Cancer trials in the USA

24 of 9129 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
NCT07261631Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer
Novartis Pharmaceuticals
Phase 1
180
New Jersey
2025-11-24
Active, closed
Daiichi Sankyo
Observational
760
New Jersey
2025-09-01
Recruiting
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1
52
California, Colorado, Illinois, Massachusetts, New York, Tennessee
2025-08-11
Recruiting
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
NCT06999187Triple Negative Breast Cancer, HER2-negative Breast Cancer, Non Small Cell Lung Cancer, Cervical Cancer
Dren Bio
Phase 1
96
Colorado, Florida, North Carolina, Oklahoma, South Carolina, Texas, Virginia
2025-06-03
Recruiting
Gilead Sciences
Phase 1/2
100
California, Georgia, Kansas, Missouri, Tennessee, Texas, Virginia
2025-04-30
Recruiting
A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors
NCT06700070Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult, Triple Negative Breast Cancer
Pure Biologics S.A.
Early Phase 1
12
Louisiana
2025-03-27
Recruiting
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
NCT06562192Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer
Novartis Pharmaceuticals
Phase 1
162
Alabama, California, Florida, Massachusetts, Michigan, Minnesota, Texas, Washington
2024-10-15
Active, closed
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
NCT06449222Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers
BioNTech SE
Phase 2
83
California, Colorado, Connecticut, Illinois, Minnesota, New Jersey, New York, Tennessee
2024-08-26
Recruiting
ProDa BioTech, LLC
Phase 1/2
51
Georgia
2024-08-20
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,530
Alabama, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia
2024-06-24
Recruiting
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
NCT06150664Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma
Compass Therapeutics
Phase 1
85
Florida, Georgia, Indiana, Massachusetts, New York, Tennessee, Washington
2024-03-19
Recruiting
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
NCT05902988Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer
Volastra Therapeutics, Inc.
Phase 1/2
200
California, Colorado, Connecticut, Illinois, Indiana, Maryland, Michigan, New York
2023-10-18
Recruiting
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
NCT06022029Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin
OncoNano Medicine, Inc.
Phase 1
168
California, Florida, Ohio, Pennsylvania, Texas, Virginia
2023-10-13
Active, closed
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
NCT05565417Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cutaneous Squamous Cell Carcinoma
Immunitas Therapeutics
Phase 1/2
67
Arizona, Colorado, Florida, Oklahoma, Oregon, Tennessee, Texas, Virginia
2022-11-28
Recruiting
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
NCT05377996Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer
Day One Biopharmaceuticals, Inc.
Phase 1/2
360
Arizona, California, Florida, Georgia, Illinois, Massachusetts, Michigan, Minnesota
2022-08-15
Active, closed
Gilead Sciences
Phase 3
443
Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2022-07-25
Active, closed
Gilead Sciences
Phase 3
623
Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa, Kentucky
2022-07-20
Recruiting
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
NCT05627960Triple Negative Breast Cancer, Hormone-Resistant Breast Cancer, Non Small Cell Lung Cancer, Mesothelioma
A&G Pharmaceutical Inc.
Phase 1
77
Maryland
2022-02-14
Recruiting
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
NCT05037825Non-Small-Cell Lung Carcinoma, Malignant Melanoma, Renal Cell Carcinoma, Triple-Negative Breast Cancer
VastBiome
Observational
800
Kentucky
2021-11-22
Active, closed
A Beta-only IL-2 ImmunoTherapY Study
NCT05086692Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer
Medicenna Therapeutics, Inc.
Phase 1/2
160
California, Florida, Georgia, Michigan, Texas
2021-08-27
Active, closed
OBI Pharma, Inc
Phase 3
575
California, Florida, Illinois, Maryland, Michigan, New Jersey, Pennsylvania, Texas
2018-12-05
Recruiting
Jina Pharmaceuticals Inc.
Phase 3
657
Georgia, Missouri, Ohio
2018-07-10
Active, closed
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
NCT03401385Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer, Non-small Cell Lung Cancer
Daiichi Sankyo Co., Ltd.
Phase 1
890
California, District of Columbia, Georgia, Maryland, Massachusetts, New York, Tennessee, Texas
2018-01-31
Rows per page Showing 1–24 of 24
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 3 November 2026. https://priyalifescience.com/clinical-trials-usa/condition/triple-negative-breast-cancer

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,129 studies in total at the last sync on 03 Nov 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 24 of those studies listing the condition Triple-Negative Breast Cancer.

How many Triple-Negative Breast Cancer trials are recruiting in the US?

16 of the 24 studies on this page are recruiting new participants as of the 03 Nov 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 8 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Triple-Negative Breast Cancer), 24 studies
PhaseStudiesRecruitingShare
Phase 18733.3%
Phase 1/26425%
Phase 36325%
Observational218.3%
Early Phase 1114.2%
Phase 2104.2%

Most active sponsors

Lead sponsors with the most studies (Triple-Negative Breast Cancer)
Lead sponsorStudiesRecruiting
Gilead Sciences42
Novartis Pharmaceuticals22
A&G Pharmaceutical Inc.11
BioNTech SE10
Compass Therapeutics11
Daiichi Sankyo10
Daiichi Sankyo Co., Ltd.10
Day One Biopharmaceuticals, Inc.11
Dren Bio11
Immunitas Therapeutics10

Top states

Top states (Triple-Negative Breast Cancer), by number of studies with a site there
StateStudies
California14
Florida12
Georgia11
Colorado9
Texas8
Arizona6
Illinois6
Tennessee6
Connecticut5
Massachusetts5
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.